Lynx1 Capital Management LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Lynx1 Capital Management LP disclosed 18 US equity positions worth $282.2m in its Q3 2024 13F filing. The largest position was MERUS N V at 31.8% of the reported book, followed by STOK and CCCC.
What did Lynx1 Capital Management LP own in Q3 2024? Top 18 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 31.8% | $89.6m | 1,793,866 | – | ||
| 2 | STOK STOKE THERAPEUTICS INC | Healthcare | 22.6% | $63.8m | 5,187,191 | – | |
| 3 | CCCC C4 THERAPEUTICS INC | Healthcare | 13.9% | $39.2m | 6,880,527 | – | |
| 4 | GHRS GH RESEARCH PLC | 9.9% | $28.1m | 4,195,894 | – | ||
| 5 | TCRX TSCAN THERAPEUTICS INC | 9.2% | $26.0m | 5,224,600 | – | ||
| 6 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 6.2% | $17.4m | 6,202,374 | – | |
| 7 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 2.4% | $6.9m | 410,830 | – | |
| 8 | PASG PASSAGE BIO INC | 2.1% | $5.9m | 8,426,955 | – | ||
| 9 | IBIO IBIO INC | 0.7% | $1.9m | 862,279 | – | ||
| 10 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.5% | $1.3m | 680,189 | – | |
| 11 | KOD KODIAK SCIENCES INC | Healthcare | 0.3% | $707.8k | 271,177 | – | |
| 12 | PIERIS PHARMACEUTICALS INC | 0.2% | $620.7k | 37,436 | – | ||
| 13 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.1% | $278.2k | 17,400 | – | ||
| 14 | BNOXN BIONOMICS LIMITED | 0.1% | $241.5k | 549,673 | – | ||
| 15 | KINIKSA PHARMACEUTICALS INTL | 0.1% | $205.7k | 8,231 | – | ||
| 16 | TENX TENAX THERAPEUTICS INC | 0.0% | $51.0k | 14,751 | – | ||
| 17 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.0% | $32.5k | 19,028 | – | |
| 18 | MNLOUSD VYNE THERAPEUTICS INC | 0.0% | $30.4k | 16,194 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.